In this report, we have explored the promise of TG2 as a potential therapeutic target in the treatment of cardiac fibrosis with a highly selective TG2 inhibitor14, using two different preclinical models representative of the reactive and replacement fibrosis that is most frequently found in heart disease. Here, TGM2 is linked to heart disorder.